Trial Profile
A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms SOPRANO
- Sponsors Actelion Pharmaceuticals
- 28 Apr 2021 Results presented at the 41st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation
- 14 Apr 2020 Status changed from active, no longer recruiting to completed.
- 17 Mar 2020 Planned End Date changed from 1 Jul 2021 to 20 Mar 2021.